{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:59:40Z","timestamp":1789851580896,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two oral antivirals for treatment of COVID-19 are available in Australia, nirmatrelvir-ritonavir, which is recommended, and molnupiravir, which is approved for use when nirmatrelvir-ritonavir is contraindicated. From 2022 to 2024, over 1.5\u00a0million Pharmaceutical Benefits Scheme (PBS) prescriptions were dispensed. We examined dispensing of antivirals in people aged 70\u2009+\u2009years in Victoria, Australia, from July 2022 to April 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We linked COVID-19 notifications in residents of Victoria (population 6.6\u00a0million) aged 70\u2009+\u2009years to data from the Australian 2021 Census of Population and Housing, Australian Immunisation Register, PBS and Medicare Benefits Scheme. We examined trends over time and compared the socio-demographic and clinical characteristics of people who received antivirals with those who received no treatment, according to the type of antiviral received. We also estimated the proportion of people that received molnupiravir and nirmatrelvir-ritonavir who had a pharmacological contraindication to nirmatrelvir-ritonavir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 76,120 people aged 70\u2009+\u2009years with a COVID-19 notification, 50,005 (66%) received an antiviral with 37,101 (74%) receiving molnupiravir. The proportion of people that received nirmatrelvir-ritonavir increased during the study period from 19% (1957\/10,256) in July 2022 to 35% (720\/2075) in April 2023. After adjusting for age and sex, characteristics associated with receipt of antivirals included RACF residence, higher income and higher education. Compared to molnupiravir, receipt of nirmatrelvir-ritonavir was greater in those with higher incomes, higher education and no COVID-19 vaccine booster in the last 6 months. The majority of people who received molnupiravir (25,378\/37101;68%) did not have a category 1 pharmacological contraindication to nirmatrelvir-ritonavir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During the study period, most COVID-19 cases in Victoria received antivirals but variations according to age, sex, socioeconomic status, residence in aged care and vaccination suggest that further efforts to identify barriers and enablers to treatment are warranted. Our findings also suggest that pharmacological contraindications to nirmatrelvir-ritonavir are not the primary reason for prescribing molnupiravir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12536-y","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:04:29Z","timestamp":1769195069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study"],"prefix":"10.1186","volume":"26","author":[{"given":"Laura J.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Scaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sumpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"12536_CR1","unstructured":"COVID-19 - Level. 3 cause | Institute for Health Metrics and Evaluation [Internet]. [cited 2025 Apr 29]. Available from: https:\/\/www.healthdata.org\/research-analysis\/diseases-injuries-risks\/factsheets\/2021-covid-19-level-3-disease"},{"key":"12536_CR2","unstructured":"Australian Institute of Health and Welfare [Internet]. 2025 [cited 2025 Apr 29]. Deaths in Australia, COVID-19 deaths. Available from: https:\/\/www.aihw.gov.au\/reports\/life-expectancy-deaths\/deaths-in-australia\/contents\/covid-19-deaths"},{"key":"12536_CR3","unstructured":"Australian Government Department of Health Disability and Ageing. Pharmaceutical Benefits Scheme (PBS) | PBS Expenditure and Prescriptions Report 1 July 2023 to 30 June 2024 [Internet]. Austra\u00adlian Government Department of Health and Aged Care; [cited 2025 Mar 28]. Available from: https:\/\/www.pbs.gov.au\/info\/statistics\/expenditure-prescriptions\/expenditure-prescriptions-report-1-july-2023-30-june-2024."},{"key":"12536_CR4","unstructured":"Australian Government Department of Health Disability and Ageing. Pharmaceutical Benefits Scheme (PBS) | [Internet]. Australian Government Department of Health and Aged Care; [cited 2025 May 26]. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/12996B-13147Y"},{"issue":"10373","key":"12536_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281\u201393.","journal-title":"Lancet"},{"key":"12536_CR6","unstructured":"Australian Institute of Health and Welfare [Internet]. 2024 [cited 2025 Oct 21]. Australia\u2019s Health Topic Summaries: COVID-19. Available from: https:\/\/www.aihw.gov.au\/reports\/australias-health\/covid-19"},{"key":"12536_CR7","unstructured":"Australian Government Department of Health Disability and Ageing. Pharmaceutical Benefits Scheme (PBS) | Molnupiravir for SARS-COV-2-infection: utilisation analysis [Internet]. Australian Govern\u00adment Department of Health and Aged Care; [cited 2025 Mar 20]. Available from: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/participants\/public-release-docs\/2024-10\/molnupiravir-for-sars-cov-2-infection-utilisation-analysis"},{"key":"12536_CR8","unstructured":"Paxlovid Co-Pack Tablets. 30 - Nirmatrelvir\u2009+\u2009Ritonavir [Internet]. [cited 2025 Oct 11]. Available from: https:\/\/www.chemistwarehouse.com.au\/buy\/141091-paxlovid-co-pack-tablets-30-nirmatrelvir-ritonavir"},{"issue":"6","key":"12536_CR9","doi-asserted-by":"publisher","first-page":"104953","DOI":"10.1016\/j.idnow.2024.104953","volume":"54","author":"D Lopez","year":"2024","unstructured":"Lopez D, Pritchard D, Sanfilippo FM, Kelty E, Page A, Etherton-Beer C, et al. Supply of nirmatrelvir\/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian pharmaceutical benefits scheme: A retrospective observational study. Infect Dis now. 2024;54(6):104953.","journal-title":"Infect Dis now"},{"issue":"4","key":"12536_CR10","first-page":"323","volume":"328","author":"BM Kuehn","year":"2022","unstructured":"Kuehn BM. Persistent disparities in COVID-19 antiviral dispensing. JAMA. 2022;328(4):323.","journal-title":"JAMA"},{"issue":"3","key":"12536_CR11","doi-asserted-by":"publisher","first-page":"e083342","DOI":"10.1136\/bmjopen-2023-083342","volume":"14","author":"A Miyawaki","year":"2024","unstructured":"Miyawaki A, Kitajima K, Iwata A, Sato D, Tsugawa Y. Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in japan: an observational study. BMJ Open. 2024;14(3):e083342.","journal-title":"BMJ Open"},{"issue":"1","key":"12536_CR12","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.1038\/s41598-024-57633-7","volume":"14","author":"DE Malden","year":"2024","unstructured":"Malden DE, McLaughlin JM, Hong V, Lewnard J, Ackerson BK, Puzniak L, et al. Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system. Sci Rep. 2024;14(1):7485.","journal-title":"Sci Rep"},{"issue":"1","key":"12536_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/imj.16254","volume":"54","author":"H Al Naji","year":"2024","unstructured":"Al Naji H, Inglis JM, Tucker E, Rowett D, Larcombe R, Medlin S, et al. Prescribing of antivirals for COVID-19 in a South Australian local health network according to statewide guidelines. Intern Med J. 2024;54(1):183\u20136.","journal-title":"Intern Med J"},{"issue":"3","key":"12536_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10875-024-01683-z","volume":"44","author":"D Shi","year":"2024","unstructured":"Shi D, Chen J, Zhao M, Tang Y, Zhao C, Jin Y, et al. Prevalence of neutralizing autoantibodies against type I interferon in a multicenter cohort of severe or critical COVID-19 cases in Shanghai. J Clin Immunol. 2024;44(3):80.","journal-title":"J Clin Immunol"},{"key":"12536_CR15","unstructured":"Breadon P, Chen I. How we analysed COVID antiviral uptake. Grattan Institute. 2024."},{"issue":"10","key":"12536_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.5694\/mja2.51949","volume":"218","author":"NL Allard","year":"2023","unstructured":"Allard NL, Canevari J, Haslett N, Cowie BC. Access to oral COVID -19 antivirals in the community: are eligibility criteria and systems ensuring equity? Med J Aust. 2023;218(10):438\u201341.","journal-title":"Med J Aust"},{"key":"12536_CR17","doi-asserted-by":"crossref","unstructured":"Gold JAW. Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code\u2013Level Social Vulnerability \u2014 United States, December 23, 2021\u2013May 21, 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2025 Jan 27];71. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7125e1.htm","DOI":"10.15585\/mmwr.mm7125e1"},{"issue":"43","key":"12536_CR18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","volume":"71","author":"TK Boehmer","year":"2022","unstructured":"Boehmer TK. Racial and ethnic disparities in outpatient treatment of COVID-19 \u2015 united States, January\u2013July 2022. MMWR Morb Mortal Wkly Rep. 2022;71(43):1359\u201365.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"12536_CR19","doi-asserted-by":"crossref","unstructured":"Thomas J, Kamalakkannan A, Prgomet M, Gardner K, McGuire P, Campbell G, et al. Oral COVID-19 antiviral prescribing in Australian general practice \u2013 a retrospective observational study. Aust J Prim Health [Internet]. 2025 Feb 11 [cited 2025 Feb 13];31(1). Available from: https:\/\/www.publish.csiro.au\/py\/PY24170","DOI":"10.1071\/PY24170"},{"key":"12536_CR20","unstructured":"National, state and territory population., June 2022 | Australian Bureau of Statistics [Internet]. 2022 [cited 2025 Mar 13]. Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/jun-2022"},{"key":"12536_CR21","unstructured":"Department of Health. Victoria A. Notification procedures for infectious diseases [Internet]. State Government of Victoria, Australia; [cited 2025 May 26]. Available from: https:\/\/www.health.vic.gov.au\/infectious-diseases\/notification-procedures-for-infectious-diseases"},{"key":"12536_CR22","unstructured":"Medicare - Services Australia [Internet]. [cited 2025 Oct 11]. Available from: https:\/\/www.servicesaustralia.gov.au\/whats-covered-medicare?context=60092"},{"issue":"4","key":"12536_CR23","doi-asserted-by":"publisher","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","volume":"8","author":"NL Pratt","year":"2018","unstructured":"Pratt NL, Kerr M, Barratt JD, Kemp-Casey A, Ellett LMK, Ramsay E, et al. The validity of the Rx-Risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system. BMJ Open. 2018;8(4):e021122.","journal-title":"BMJ Open"},{"key":"12536_CR24","doi-asserted-by":"crossref","unstructured":"Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, et al. Effectiveness of COVID-19 Vaccination Against Covid-19 Specific and All-Cause Mortality in Older Australians [Internet]. Rochester, NY; 2023 [cited 2023 Jun 2]. Available from: https:\/\/papers.ssrn.com\/abstract=4445191","DOI":"10.2139\/ssrn.4445191"},{"key":"12536_CR25","unstructured":"Liverpool. COVID-19 Interactions [Internet]. [cited 2025 Mar 13]. Available from: https:\/\/www.covid19-druginteractions.org\/checker"},{"key":"12536_CR26","unstructured":"Privacy Act 1988 [Internet]. scheme\u2009=\u2009AGLSTERMS.AglsAgent; corporateName\u2009=\u2009Office Parliamentary Counsel; address\u2009=\u2009Locked Bag 30 Kingston ACT 2604; contact\u2009=\u2009+\u200961 2 6120 1400; 2025 [cited 2025 May 12]. Available from: https:\/\/www.legislation.gov.au\/C2004A03712\/latest"},{"issue":"1","key":"12536_CR27","first-page":"2521858","volume":"2","author":"O Eales","year":"2025","unstructured":"Eales O, Teo M, Price DJ, Hao T, Ryan GE, Senior KL, et al. Temporal trends in test-seeking behaviour during the COVID-19 pandemic. Math Med Life Sci. 2025;2(1):2521858.","journal-title":"Math Med Life Sci"},{"key":"12536_CR28","doi-asserted-by":"crossref","unstructured":"Heer CV, Majumdar SS, Parta I, Martinie M, Dawson R, West D, et al. Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study. Lancet Reg Health \u2013 West Pac. 2023;41((Van Heer, Majumdar, Parta, Martinie, Dawson, West, Hewett, Lister, Sutton, Cowie) Department of Health, Victorian Government, Melbourne, VIC, Australia):100917.","DOI":"10.1016\/j.lanwpc.2023.100917"},{"key":"12536_CR29","doi-asserted-by":"crossref","unstructured":"Robinson EJ, Manoharan L, Cowie BC, Lister DM. Inequities in COVID-19 antiviral dispensation in Victoria, Australia. 2025.","DOI":"10.31128\/AJGP-06-24-7312"},{"key":"12536_CR30","doi-asserted-by":"crossref","unstructured":"Thomas J, Kamalakkannan A, Prgomet M, Gardner K, McGuire P, Campbell G, et al. Oral COVID-19 antiviral prescribing in Australian general practice \u2013 a retrospective observational study. Aust J Prim Health [Internet]. 2025 Feb 11 [cited 2025 Oct 11];31(1). Available from: https:\/\/www.publish.csiro.au\/PY\/PY24170","DOI":"10.1071\/PY24170"},{"issue":"1","key":"12536_CR31","doi-asserted-by":"publisher","first-page":"33342309","DOI":"10.17061\/phrp33342309","volume":"34","author":"NE Clarke","year":"2024","unstructured":"Clarke NE, O\u2019Keeffe J, Yerramilli A, Bartolo C, Mothobi N, Muleme M, et al. Use of targeted SMS messaging to encourage COVID-19 oral antiviral uptake in South West Victoria. Public Health Res Pract. 2024;34(1):33342309.","journal-title":"Public Health Res Pract"},{"issue":"3","key":"12536_CR32","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/ciac687","volume":"76","author":"TCF Yip","year":"2023","unstructured":"Yip TCF, Lui GCY, Lai MSM, Wong VWS, Tse YK, Ma BHM, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin Infect Dis Off Publ Infect Dis Soc Am. 2023;76(3):e26\u201333.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"11","key":"12536_CR33","doi-asserted-by":"publisher","first-page":"E2241434","DOI":"10.1001\/jamanetworkopen.2022.41434","volume":"5","author":"KL Bajema","year":"2022","unstructured":"Bajema KL, Wang XQ, Hynes DM, Rowneki M, Hickok A, Cunningham F, et al. Early adoption of Anti-SARS-CoV-2 pharmacotherapies among US veterans with mild to moderate COVID-19, January and February 2022. JAMA Netw Open. 2022;5(11):E2241434.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"12536_CR34","doi-asserted-by":"publisher","first-page":"e000276","DOI":"10.1136\/bmjmed-2022-000276","volume":"2","author":"ACA Green","year":"2023","unstructured":"Green ACA, Curtis HJ, Higgins R, Nab L, Mahalingasivam V, Smith RM, et al. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in opensafely. BMJ Med. 2023;2(1):e000276.","journal-title":"BMJ Med"},{"key":"12536_CR35","unstructured":"Australian Institute of Health and Welfare. Australian Institute of Health and Welfare. 2025 [cited 2025 Apr 29]. Hospitalisations and deaths following COVID-19, 2020\u20132022: a linked data analysis, About. Available from: https:\/\/www.aihw.gov.au\/reports\/covid-19\/hospitalisations-deaths-following-covid19-2020-22\/contents\/about"},{"key":"12536_CR36","unstructured":"Australian Government. COVID-19 outbreaks in Australian residential aged care facilities [Internet], Department of Health and Aged Care. 2024 Jan:18. Available from: https:\/\/www.health.gov.au\/sites\/default\/files\/2024-01\/covid-19-outbreaks-in-australian-residential-aged-care-facilities-25-january-2024.pdf"},{"key":"12536_CR37","doi-asserted-by":"crossref","unstructured":"Monach PA. Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 \u2014 Veterans Health Administration, March\u2013September 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2024 [cited 2024 Jan 29];73. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7303a2.htm","DOI":"10.15585\/mmwr.mm7303a2"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12536-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:03:04Z","timestamp":1781629384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12536-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12536"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12536-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received a Notification of Exemption from Human Research Ethics Review from the Research Ethics and Integrity Committee at the University of Queensland. This included a waiver of consent from participants. To maintain confidentiality, data were de-identified prior to being provided for this research in accordance with Australian privacy legislation. The study adhered to the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}